Next Generation Electronic Cigarette Patent Portfolio for Sale by ICAP Patent Brokerage

CHICAGO, June 20, 2013 /PRNewswire/ -- ICAP Patent Brokerage announces for sale a patent portfolio of heatless and smokeless cigarette technology that exclusively advances electronic cigarette science.

(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

"We are excited to offer this innovative cigarette replacement technology to our global base of patent buyers. The portfolio for sale offers the next generation of e-cigarette technology, which is reliable, convenient, and 90% more cost-effective by eliminating the need for any battery or mechanical components like those used in all existing e-cigarettes," says Dean Becker, CEO of ICAP Patent Brokerage.

Key Characteristics & Benefits
A variety of electronic cigarettes have hit the market in recent months. Retail sales for these tobacco alternatives will likely eclipse U.S. market sales for tobacco cigarettes within the next decade. As the e-cigarette industry experiences rapid growth this IP package is highly relevant to companies interested in joining this emerging market.

The disclosed smoking substitute is designed to have the feel, draw, and full taste satisfaction identical to that of tobacco cigarettes, thus providing a realistic smoking experience for users. However, this technology operates using only inhaled air rather than cartridges or batteries that require replacement. The patented smokeless cigarette contains a filter system and distributor. Inhaled air passes through a nicotine-moistened distributor to release nicotine vapor that is completely invisible. Simultaneously, the aerodynamic distributor filter system within the cigarette tube automatically recharges itself. Plus, this smokeless cigarette can be used anywhere without restriction as it does not emit any smoke, mist, or odor. Mist-emitting electronic cigarettes (like smoke-emitting traditional cigarettes) are already banned for use in many areas.

The smokeless cigarette industry is still in its early stages and experiencing accelerated growth. Every competitor will require strong IP protection to survive fierce market competition. The patent for sale has already been challenged in court and prevailed as valid. Even more importantly, all electronic cigarettes are still awaiting Food and Drug Administration (FDA) registration and regulations. A legal opinion in writing has already been issued by the FDA stating they will not regulate products made with this patented technology. Due to these facts, the new owner of this IP portfolio is well-positioned among the hundreds of brands of e-cigarettes still facing potential legal challenges and unknown pending FDA regulations.

To view a demonstration of the technology covered by U.S. Patent No. 6,769,436 and additional patent pending, click here.

To learn more about the assets available for sale in this portfolio:
Contact Dean Becker of ICAP Patent Brokerage at (561) 573-0405 or via email at Dean.Becker@us.icap.com.

Follow us on Twitter (@ICAP_Auction_IP) and join our LinkedIn group.

About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.

About ICAP
ICAP is the world's leading interdealer broker and provider of post trade risk and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, go to www.icap.com.

SOURCE ICAP Patent Brokerage



RELATED LINKS
http://icappatentbrokerage.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.